Melanoma Clinical Trials

Showing 1-20 of 705 trials

IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors

NCT05039801

To find the highest tolerable dose of IACS-6274 that can be given alone, in combination with bevacizumab and paclitaxel, or in combination with capivasertib to patients who have solid tumors. The safety and tolerability of the study drug(s) will also be studied.

Advanced Endometrial CarcinomaAdvanced Head and Neck Squamous Cell CarcinomaAdvanced Malignant Solid Neoplasm+35 more

M.D. Anderson Cancer Center54 participantsStarted Sep 2021

Houston, Texas, United States

ACTIVE_NOT_RECRUITINGPHASE2

Dinaciclib in Treating Patients With Stage IV Melanoma

NCT00937937

This phase II trial is studying the side effects and how well dinaciclib works in treating patients with stage IV melanoma. Dinaciclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Acral Lentiginous MelanomaCutaneous Nodular MelanomaLentigo Maligna Melanoma+4 more

National Cancer Institute (NCI)72 participantsStarted Jul 2009

Mobile, Alabama, United States • Fort Smith, Arkansas, United States • Little Rock, Arkansas, United States +187 more locations

IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors

Dinaciclib in Treating Patients With Stage IV Melanoma

Related Searches

Pilot Trial of Supplemental Vitamin A and Nicotinamide

Cediranib Maleate and Selumetinib Sulfate in Treating Patients With Solid Malignancies

Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma

A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration Both Before and After Surgery for High-Risk Melanoma

Harvesting Cells for Experimental Cancer Treatments

A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

Pembrolizumab in Treating Patients With Desmoplastic Melanoma That Can or Cannot Be Removed by Surgery

NOTION: iN-home Sampling Of cyTokines in ImmunOtherapy patieNts

SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma

Ketogenic Dietary Intervention to Improve Response to Immunotherapy in Patients With Metastatic Melanoma and Metastatic Kidney Cancer

Pharmacokinetics, Safety, and Immunogenicity Comparison of Bmab1700 and Opdivo® as Adjuvant Monotherapy in Participants With Melanoma

(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma

A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors

Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma

Narrow Excision Versus Wide Excision for the Treatment of Adults With Invasive Cutaneous Melanoma, ICEMAN Trial

A Study Comparing 3 Study Medicines (Encorafenib, Binimetinib, Pembrolizumab) to 2 Study Medicines (Ipilimumab and Nivolumab) in Patients With Advanced Melanoma

Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma

Characterisation of T Lymphocytes, NK Cells and Macrophages in Melanoma Patients